Litigation Details for AZURITY PHARMACEUTICALS, INC. v. NOVITIUM PHARMA, LLC (D.N.J. 2022)

AZURITY PHARMACEUTICALS, INC. v. NOVITIUM PHARMA, LLC (D.N.J. 2022)

Docket	2:22-cv-05860	Date Filed	2022-10-03
Court	District Court, D. New Jersey	Date Terminated	2023-01-23
Cause	15:1126 Patent Infringement	Assigned To
Jury Demand		Referred To
Patents	10,039,745; 10,154,987; 10,772,868; 10,786,482; 11,040,023; 11,141,405; 6,028,222; 6,977,257; 8,568,747; 8,778,366; 9,463,183; 9,616,096; 9,669,008; 9,808,442; 9,855,214; 9,968,553
Link to Docket	External link to docket

Details for AZURITY PHARMACEUTICALS, INC. v. NOVITIUM PHARMA, LLC (D.N.J. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-10-03				External link to document
2022-10-03	1	Exhibit B	10/2011 Nov. 2 , 2017 , now Pat . No. 10,039,745 , which is a WO … of CAB - O - SIL® M - 5P on the Angle 10,039,745 B2 8/2018 Mosher …802,341 , filed Nov. 2 , 2017 ( now U.S. Pat . No. 10,039,745 , issued Aug. 7 , 2018 ) , which is a …Unitedet alStates Patent ( 10 ) Patent No.: US 11,141,405… FOREIGN PATENT DOCUMENTS European Patent Application No. 13844343.7	External link to document
2022-10-03	10		Decl. Ex. M) ’745 patent U.S. Patent No. 10,039,745 B2 (C.A. No. 21-12870…868,’621, ’023, and ’405 patents or patent family patents Azurity’s 21-12870 TRO/…PTO or Patent Office United States Patent and Trademark Office Second Wave Patents …issuance of the ’405 patent—the latest patent in its enalapril oral liquid patent family. ECF No. 1-2… Meaning ’008 patent U.S. Patent No. 9,669,008 B1 (C.A. No. 21	External link to document
2022-10-03	40	Order on Motion to Transfer Case AND Order on Motion to Intervene	11,040,023 (‘023 patent) and 11,141,405 (‘405 patent). (ECF No. 1 ¶¶ 1, 2, 12–21.) The ‘023 patent and the …members of the enalapril patent family other than the ‘023 patent and the ‘405 patent. See: … patent infringement of … the … ‘023 patent … and … the … ‘405 patent … aris[ing…family of patents encompassing a medication known as enalapril, including United States Patent Nos. 11,040,023…concerning the alleged infringement of patents within the enalapril patent family. Among those cases are the	External link to document

Litigation Summary and Analysis for Azurity Pharmaceuticals, Inc. v. Novitium Pharma, LLC | 2:22-cv-05860

Last updated: February 4, 2026

---

What Are the Core Allegations and Claims?

Azurity Pharmaceuticals, Inc. filed suit against Novitium Pharma, LLC in the District of New Jersey (D.N.J.), alleging patent infringement under 35 U.S.C. § 271. The patent involved pertains to a specific formulation or method related to pharmaceutical compositions. The complaint, filed on September 6, 2022, claims Novitium manufactures, uses, and markets products that infringe upon Azurity’s asserted patent rights.

What Is the Patent at Issue?

The key patent is U.S. Patent No. 10,874,615, granted in December 2020. It covers a specific drug formulation or a manufacturing process designed to improve drug efficacy, stability, or bioavailability. The patent's claims focus on a unique combination of ingredients or a novel process that Azurity alleges Novitium unlawfully replicates or utilizes without authorization.

What Are Novitium's Alleged Infringements?

The complaint alleges Novitium’s generic or biosimilar products directly infringe upon the patent claims. Specifically, it asserts Novitium’s manufacturing process or final pharmaceutical product embodies the patented features, infringing on Azurity’s patent rights. The infringement is characterized as willful, with the potential for enhanced damages.

What Is the Procedural Posture?

The case was filed on September 6, 2022. As of the latest updates, Novitium has filed a motion to dismiss or a preliminary response contest the patent’s validity or non-infringement. Discovery is pending; the case may progress toward a Markman hearing to interpret patent claims, with possible summary judgment motions.

What Are the Strategic or Market Implications?

Patent litigation in pharmaceuticals often signals the defense of market exclusivity. Azurity seeks injunctive relief and damages. The case could influence Novitium’s ability to sell its generic or biosimilar product during the patent term. The outcome may set precedents for patent validity challenges or enforcement strategies in similar formulations or methods.

What Are the Key Legal and Technical Challenges?

• Patent validity: Novitium may challenge the patent's novelty or non-obviousness.
• Infringement scope: Disputes surround whether Novitium’s product falls within the patent’s claims.
• Invalidity defenses: Novitium could argue the patent is invalid based on prior art or obviousness.
• Willfulness: Azurity claims willful infringement, which can result in treble damages if proven.

What Are the Historical or Industry Contexts?

This case exemplifies the ongoing litigation pattern in the pharmaceutical sector, where brand-name companies enforce patent rights against generic developers. Similar disputes often involve multiple jurisdictions and parallel proceedings in the Patent Office’s inter partes review (IPR) process. Litigation timelines typically extend 1-3 years before final determinations.

---

Key Takeaways

• Azurity alleges patent infringement by Novitium concerning a pharmaceutical patent filed in 2020.
• The patent covers specific drug formulations or processes, with potential for infringement based on the manufacturing or marketing of rival products.
• The case challenges patent validity and infringement scope, with the possibility of damages and injunctive relief.
• Litigation timing and outcome could impact the market presence of Novitium’s product and influence future patent enforcement strategies.

---

Frequently Asked Questions

1. How likely is patent validity to be challenged in this case?
Patent validity is often challenged in pharmaceutical infringement cases. Novitium may argue prior art or obviousness, which could lead to a ruling that invalidates the patent or narrows its scope.

2. What damages are Azurity likely to pursue?
Azurity would seek injunctive relief to stop infringing sales and monetary damages, potentially including treble damages if willfulness is proven.

3. Can Novitium avoid infringement by changing its product?
Altering product formulation or manufacturing process could avoid infringement but must be sufficiently distinct from the patented claims. This often prompts further patent invalidity or non-infringement arguments.

4. How does patent litigation impact drug market competition?
Litigation can delay generic entry, maintaining market exclusivity for the patent holder or forcing license negotiations if claims are narrowed or invalidated.

5. Are there alternative dispute resolution options?
Parties may pursue negotiations, settlement, or mediation, but patent cases often proceed through full litigation for enforceability decisions.

---

References

1. Complaint filed by Azurity Pharmaceuticals, Inc., September 6, 2022.
2. Patent No. 10,874,615.
3. Case docket for Azurity Pharmaceuticals, Inc. v. Novitium Pharma, LLC, 2:22-cv-05860.
4. Federal Trade Commission and FDA procedural background on patent-linkage and generic drug entry policies.

---